Advances in research on cutoffs for blood biomarkers in Alzheimer’s disease

Shuheng WANG, Yamei TANG, Jianping JIA

Chinese Journal of Alzheimer's Disease and Related Disorders ›› 2026, Vol. 9 ›› Issue (5) : 337-343.

PDF(907 KB)
Home Journals Chinese Journal of Alzheimer's Disease and Related Disorders
Chinese Journal of Alzheimer's Disease and Related Disorders

Abbreviation (ISO4): Chinese Journal of Alzheimer's Disease and Related Disorders      Editor in chief: Jun WANG

About  /  Aim & scope  /  Editorial board  /  Indexed  /  Contact  / 
PDF(907 KB)
Chinese Journal of Alzheimer's Disease and Related Disorders ›› 2026, Vol. 9 ›› Issue (5) : 337-343. DOI: 10.3969/j.issn.2096-5516.2026.05.009
Reviews

Advances in research on cutoffs for blood biomarkers in Alzheimer’s disease

Author information +
History +

Abstract

Blood biomarkers are increasingly used in Alzheimer’s disease (AD). Their clinical use depends on appropriate cutoff definitions and consistent interpretation of results. Current cutoff strategies are mainly based on external reference standards, receiver operating characteristic (ROC) analysis, reference intervals, and population distributions. More recent approaches include ratio-based measures, multi-marker combinations, gray-zone classification, and longitudinal monitoring, particularly when biomarker values fall near the cutoff or when results are interpreted in clinically diverse populations. Biomarker levels may also be influenced by age, apolipoprotein E ε4 genotype, comorbidities, and analytical platform differences, which limit the use of a universal cutoff across different settings. Future studies should move beyond one-time classification toward task-specific interpretation and repeated measurement over time to improve clinical use in screening, diagnosis, and follow-up.

Key words

Alzheimer’s disease / Blood biomarkers / Cutoff / Gray zone / Longitudinal monitoring

Cite this article

Download Citations
Shuheng WANG , Yamei TANG , Jianping JIA. Advances in research on cutoffs for blood biomarkers in Alzheimer’s disease[J]. Chinese Journal of Alzheimer's Disease and Related Disorders. 2026, 9(5): 337-343 https://doi.org/10.3969/j.issn.2096-5516.2026.05.009

References

[1]
Smirnov D S, Ashton N J, Blennow K, et al. Plasma biomarkers for Alzheimer’s disease in relation to neuropathology and cognitive change[J/OL]. Acta Neuropathol, 2022, 143(4): 487-503. https://doi.org/10.1007/s00401-022-02408-5.
[2]
Jack C R, Bennett D A, Blennow K, et al. NIA-AA research framework: Toward a biological definition of Alzheimer’s disease[J/OL]. Alzheimers Dement, 2018, 14(4): 535-562. https://doi.org/10.1016/j.jalz.2018.02.018.
[3]
Mielke M M, Hagen C E, Xu J, et al. Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography[J/OL]. Alzheimers Dement, 2018, 14(8): 989-997. https://doi.org/10.1016/j.jalz.2018.02.013.
[4]
Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer’s disease: Relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia[J/OL]. Nat Med, 2020, 26(3): 379-386. https://doi.org/10.1038/s41591-020-0755-1.
[5]
Palmqvist S, Janelidze S, Quiroz Y T, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders[J/OL]. JAMA, 2020, 324(8): 772-781. https://doi.org/10.1001/jama.2020.12134.
[6]
Barthélemy N R, Horie K, Sato C, et al. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease[J/OL]. J Exp Med, 2020, 217(11): e20200861. https://doi.org/10.1084/jem.20200861.
[7]
Verberk I M W, Thijssen E, Koelewijn J, et al. Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology[J/OL]. Alzheimers Res Ther, 2020, 12(1): 118. https://doi.org/10.1186/s13195-020-00682-7.
[8]
Pereira J B, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease[J/OL]. Brain, 2021, 144(11): 3505-3516. https://doi.org/10.1093/brain/awab223.
[9]
Mattsson N, Andreasson U, Zetterberg H, et al. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease[J/OL]. JAMA Neurol, 2017, 74(5): 557-566. https://doi.org/10.1001/jamaneurol.2016.6117.
[10]
Preische O, Schultz S A, Apel A, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease[J/OL]. Nat Med, 2019, 25(2): 277-283. https://doi.org/10.1038/s41591-018-0304-3.
[11]
Schindler S E, Petersen K K, Saef B, et al. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology[J/OL]. Alzheimers Dement, 2024, 20(11): 8074-8096. https://doi.org/10.1002/alz.14315.
[12]
Janelidze S, Teunissen C E, Zetterberg H, et al. Head-to-Head comparison of 8 plasma amyloid-β 42/40 assays in Alzheimer disease[J/OL]. JAMA Neurol, 2021, 78(11): 1375-1382. https://doi.org/10.1001/jamaneurol.2021.3180.
[13]
Jiang Y, Uhm H, Ip F C, et al. A blood-based multi-pathway biomarker assay for early detection and staging of Alzheimer’s disease across ethnic groups[J/OL]. Alzheimers Dement, 2024, 20(3): 2000-2015. https://doi.org/10.1002/alz.13676.
[14]
Zhong H, Zhou X, Uhm H, et al. Using blood transcriptome analysis for Alzheimer’s disease diagnosis and patient stratification[J/OL]. Alzheimers Dement, 2024, 20(4): 2469-2484. https://doi.org/10.1002/alz.13691.
[15]
Schindler S E, Galasko D, Pereira A C, et al. Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer’s Disease[J/OL]. Nat Rev Neurol, 2024, 20(7): 426-439. https://doi.org/10.1038/s41582-024-00977-5.
[16]
Hansson O, Edelmayer R M, Boxer A L, et al. The Alzheimer’s association appropriate use recommendations for blood biomarkers in Alzheimer’s disease[J/OL]. Alzheimers Dement, 2022, 18(12): 2669-2686. https://doi.org/10.1002/alz.12756.
[17]
Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJC, et al. A practical guide to immunoassay method validation[J/OL]. Front Neurol, 2015, 6: 179. https://doi.org/10.3389/fneur.2015.00179.
[18]
Hansson O. Biomarkers for neurodegenerative diseases[J/OL]. Nat Med, 2021, 27(6): 954-963. https://doi.org/10.1038/s41591-021-01382-x.
[19]
Henny J, Petitclerc C, Fuentes-Arderiu X, et al. Need for revisiting the concept of reference values[J/OL]. Clin Chem Lab Med, 2000, 38(7): 589-595. https://doi.org/10.1515/CCLM.2000.085.
[20]
Simrén J, Andreasson U, Gobom J, et al. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5-90 years[J/OL]. Brain Commun, 2022, 4( 4): fcac174. https://doi.org/10.1093/braincomms/fcac174.
[21]
Palmqvist S, Whitson H E, Allen L A, et al. Alzheimer’s association clinical practice guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer’s disease within specialized care settings[J/OL]. Alzheimers Dement, 2025, 21(7): e70535. https://doi.org/10.1002/alz.70535.
[22]
Obuchowski N A, Bullen J A. Receiver operating characteristic (ROC) curves: Review of methods with applications in diagnostic medicine[J/OL]. Phys Med Biol, 2018, 63(7): 07TR01. https://doi.org/10.1088/1361-6560/aab4b1.
[23]
Ruopp M D, Perkins N J, Whitcomb B W, et al. Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection[J/OL]. Biom J, 2008, 50(3): 419-430. https://doi.org/10.1002/bimj.200710415.
[24]
Barthélemy N R, Salvadó G, Schindler S E, et al. Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests[J/OL]. Nat Med, 2024, 30(4): 1085-1095. https://doi.org/10.1038/s41591-024-02869-z.
[25]
Palmqvist S, Warmenhoven N, Anastasi F, et al. Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform[J/OL]. Nat Med, 2025, 31(6): 2036-2043. https://doi.org/10.1038/s41591-025-03622-w.
[26]
Pan F, Huang L, Wang Y, et al. Plasma P‐tau217, GFAP, and NfL as biomarkers for Alzheimer’s disease: Role in disease stratification, pathological progression, and cognitive decline[J/OL]. Alzheimers Dement, 2025, 21(12): e70987. https://doi.org/10.1002/alz.70987.
[27]
Warmenhoven N, Salvadó G, Janelidze S, et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests[J/OL]. Brain, 2025, 148(2): 416-431. https://doi.org/10.1093/brain/awae346.
[28]
Hansson O, Blennow K, Zetterberg H, et al. Blood biomarkers for Alzheimer’s disease in clinical practice and trials[J/OL]. Nat Aging, 2023, 3(5): 506-519. https://doi.org/10.1038/s43587-023-00403-3.
[29]
Mielke M M, Fowler N R. Alzheimer disease blood biomarkers: considerations for population-level use[J/OL]. Nat Rev Neurol, 2024, 20(8): 495-504. https://doi.org/10.1038/s41582-024-00989-1.
[30]
Palmqvist S, Tideman P, Mattsson-Carlgren N, et al. Blood biomarkers to detect alzheimer disease in primary care and secondary care[J/OL]. JAMA, 2024, 332(15): 1245-1257. https://doi.org/10.1001/jama.2024.13855.
[31]
Jiang W, Liu J, Wu Y, et al. Establishment and verification of reference intervals for Alzheimer’s disease plasma biomarkers based on evaluation of pre-analytical procedures: a multicenter study[J/OL]. Alzheimers Dement (Amst), 2025, 17(4): e70194. https://doi.org/10.1002/dad2.70194.
[32]
Ce T, Imw V, Eh T, et al. Blood-based biomarkers for Alzheimer’s disease: Towards clinical implementation[J/OL]. The Lancet Neurology, 2022, 21(1). https://doi.org/10.1016/S1474-4422(21)00361-6.
[33]
Milà-Alomà M, Ashton N J, Shekari M, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease[J/OL]. Nat Med, 2022, 28(9): 1797-1801. https://doi.org/10.1038/s41591-022-01925-w.
[34]
Schindler S E, Bollinger J G, Ovod V, et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis[J/OL]. Neurology, 2019, 93(17): e1647-e1659. https://doi.org/10.1212/WNL.0000000000008081.
[35]
Zhong X, Wang Q, Yang M, et al. Plasma p-tau217 and p-tau217/Aβ1-42 are effective biomarkers for identifying CSF- and PET imaging-diagnosed Alzheimer’s disease:Insights for research and clinical practice[J/OL]. Alzheimers Dement, 2025, 21(2): e14536. https://doi.org/10.1002/alz.14536.
[36]
Hazan J, Abel E, Rosa Grilo M, et al. How well do plasma Alzheimer’s disease biomarkers reflect the CSF amyloid status?[J/OL]. J Neurol Neurosurg Psychiatry, 2025, 96(6): 566-572. https://doi.org/10.1136/jnnp-2024-334122.
[37]
Jonaitis E M, Janelidze S, Cody K A, et al. Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease[J/OL]. Brain Commun, 2023, 5(2): fcad057. https://doi.org/10.1093/braincomms/fcad057.
[38]
Ashton N J, Brum W S, Di Molfetta G, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology[J/OL]. JAMA Neurol, 2024, 81(3): 255-263. https://doi.org/10.1001/jamaneurol.2023.5319.
[39]
Guo Y, Shen X N, Wang H F, et al. The dynamics of plasma biomarkers across the Alzheimer’s continuum[J/OL]. Alzheimers Res Ther, 2023, 15(1): 31. https://doi.org/10.1186/s13195-023-01174-0.
[40]
Cooper J G, Stukas S, Ghodsi M, et al. Age specific reference intervals for plasma biomarkers of neurodegeneration and neurotrauma in a canadian population[J/OL]. Clin Biochem, 2023, 121-122: 110680. https://doi.org/10.1016/j.clinbiochem.2023.110680.
[41]
Sjögren M, Vanderstichele H, Agren H, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values[J]. Clin Chem, 2001, 47(10): 1776-1781.
[42]
Gong J, Harris K, Peters S A E, et al. Reproductive factors and the risk of incident dementia: A cohort study of UK Biobank participants[J/OL]. PLo S Med, 2022, 19(4): e1003955. https://doi.org/10.1371/journal.pmed.1003955.
[43]
Duarte AC, Hrynchak M V, Gonçalves I, et al. Sex hormone decline and amyloid β synthesis, transport and clearance in the brain[J/OL]. J Neuroendocrinol, 2016, 28(11). https://doi.org/10.1111/jne.12432.
[44]
Hu YT, Boonstra J, Mc Gurran H, et al. Sex differences in the neuropathological hallmarks of Alzheimer’s disease: Focus on cognitively intact elderly individuals[J/OL]. Neuropathol Appl Neurobiol, 2021, 47(7): 958-966. https://doi.org/10.1111/nan.12729.
[45]
Wei S, Gao L, Jiang Y, et al. Apolipoprotein E ε4 Allele is associated with plasma amyloid beta and amyloid beta transporter levels: A cross-sectional study in a rural area of Xi’an, China[J/OL]. Am J Geriatr Psychiatry, 2020, 28(2): 194-204. https://doi.org/10.1016/j.jagp.2019.06.011.
[46]
Graff-Radford N R, Besser L M, Crook J E, et al. Neuropathologic differences by race from the national Alzheimer’s coordinating center[J/OL]. Alzheimers Dement, 2016, 12(6): 669-677. https://doi.org/10.1016/j.jalz.2016.03.004.
[47]
Cousins K A Q, Korecka M, Wan Y, et al. Comparison of plasma p-tau217/Aβ42, p-tau217, and Aβ42/Aβ40 biomarkers by race to detect Alzheimer’s disease[J/OL]. Alzheimers Dement, 2025, 21(8): e70469. https://doi.org/10.1002/alz.70469.
[48]
Windon C, Iaccarino L, Mundada N, et al. Comparison of plasma and CSF biomarkers across ethnoracial groups in the ADNI[J/OL]. Alzheimers Dement (Amst), 2022, 14(1): e12315. https://doi.org/10.1002/dad2.12315.
[49]
Howell J C, Watts K D, Parker M W, et al. Race modifies the relationship between cognition and Alzheimer’s disease cerebrospinal fluid biomarkers[J/OL]. Alzheimers Res Ther, 2017, 9(1): 88. https://doi.org/10.1186/s13195-017-0315-1.
[50]
Hajjar I, Yang Z, Okafor M, et al. Association of plasma and cerebrospinal fluid Alzheimer disease biomarkers with race and the role of genetic ancestry, vascular comorbidities, and neighborhood factors[J/OL]. JAMA Netw Open, 2022, 5(10): e2235068. https://doi.org/10.1001/jamanetworkopen.2022.35068.
[51]
Liu Z, Shi D, Cai Y, et al. Pathophysiology characterization of Alzheimer’s disease in South China’s aging population: For the Greater-Bay-Area healthy aging brain study (GHABS)[J/OL]. Alzheimers Res Ther, 2024, 16(1): 84. https://doi.org/10.1186/s13195-024-01458-z.
[52]
Wang J, Huang S, Lan G, et al. Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer’s disease in clinical and community cohorts[J/OL]. Alzheimers Dement, 2025, 21(3): e70038. https://doi.org/10.1002/alz.70038.
[53]
Li LM, Che P, Liu D, et al. Diagnostic and discriminative accuracy of plasma phosphorylated tau 217 for symptomatic Alzheimer’s disease in a Chinese cohort[J/OL]. J Prev Alzheimers Dis, 2025, 12(5): 100092. https://doi.org/10.1016/j.tjpad.2025.100092.
[54]
He Y, Du Y, Liu D, et al. Diagnostic performance of plasma p-tau217 levels measured with different assays for Alzheimer’s disease[J/OL]. Transl Psychiatry, 2026. https://doi.org/10.1038/s41398-026-04043-0.
[55]
Giacomucci G, Tabbì S M R, Ingannato A, et al. Refining Alzheimer’s disease biological diagnosis with plasma biomarkers:Resolving p-tau217 “gray zone” with p-tau181 integration[J/OL]. Alzheimers Dement (Amst), 2026, 18(1): e70285. https://doi.org/10.1002/dad2.70285.
[56]
Piura Y D, Figdore D J, Lachner C, et al. Diagnostic performance of plasma p-tau217 and Aβ42/40 biomarkers in the outpatient memory clinic[J/OL]. Alzheimers Dement, 2025, 21(6): e70316. https://doi.org/10.1002/alz.70316.
[57]
Kirsebom B E, Gonzalez-Ortiz F, Vigneswaran S, et al. Repeated plasma p-tau217 measurements to monitor clinical progression heterogeneity[J/OL]. Alzheimers Dement, 2025, 21(5): e70319. https://doi.org/10.1002/alz.70319.
[58]
Bilgel M, An Y, Walker K A, et al. Longitudinal changes in Alzheimer’s-related plasma biomarkers and brain amyloid[J/OL]. Alzheimers Dement, 2023, 19(10): 4335-4345. https://doi.org/10.1002/alz.13157.
[59]
Wojdała A L, Vanbrabant J, Bayoumy S, et al. Analytical and clinical performance of eight Simoa® and Lumipulse® assays for automated measurement of plasma p-tau181 and p-tau217[J/OL]. Alzheimers Res Ther, 2024, 16(1): 266. https://doi.org/10.1186/s13195-024-01630-5.
[60]
Ashton N J, Keshavan A, Brum W S, et al. The Alzheimer’s association global biomarker standardization consortium (GBSC) plasma phospho-tau round robin study[J/OL]. Alzheimers Dement, 2025, 21(2): e14508. https://doi.org/10.1002/alz.14508.
[61]
Mielke M M, Anderson M, Ashford J W, et al. Recommendations for clinical implementation of blood-based biomarkers for Alzheimer’s disease[J/OL]. Alzheimers Dement, 2024, 20(11): 8216-8224. https://doi.org/10.1002/alz.14184.
[62]
Grande G, Valletta M, Rizzuto D, et al. Blood-based biomarkers of Alzheimer’s disease and incident dementia in the community[J/OL]. Nat Med, 2025, 31(6): 2027-2035. https://doi.org/10.1038/s41591-025-03605-x.
[63]
Pahlke S, Kahale L A, Mahinrad S, et al. Blood-based biomarkers for detecting Alzheimer’s disease pathology in cognitively impaired individuals within specialized care settings: A systematic review and meta-analysis[J/OL]. Alzheimers Dement, 2025, 21(11): e70828. https://doi.org/10.1002/alz.70828.
[64]
U.S. Food and Drug Administration. FDA clears first blood test used in diagnosing Alzheimer’s disease[EB/OL]. (2025-05-16)[2026-05-07]. https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease.
[65]
Trieu C, Van Harten A C, Van Leeuwenstijn M S S A, et al. Longitudinal Blood-Based biomarkers and clinical progression in subjective cognitive decline[J/OL]. JAMA Netw Open, 2025, 8(12): e2545862. https://doi.org/10.1001/jamanetworkopen.2025.45862.
[66]
Sperling R A, Donohue M C, Rissman R A, et al. Amyloid and tau prediction of cognitive and functional decline in unimpaired older individuals:Longitudinal data from the A4 and LEARN Studies[J/OL]. J Prev Alzheimers Dis, 2024, 11(4): 802-813. https://doi.org/10.14283/jpad.2024.122.
[67]
Rissman R A, Donohue M C, Langford O, et al. Longitudinal phospho-tau217 predicts amyloid positron emission tomography in asymptomatic Alzheimer’s disease[J/OL]. J Prev Alzheimers Dis, 2024, 11(4): 823-830. https://doi.org/10.14283/jpad.2024.134.

Footnotes

利益冲突声明 所有作者在本研究中均不存在利益冲突。

PDF(907 KB)

Accesses

Citation

Detail

Sections
Recommended

/

〈 〉